Skip to Content

You are here

Active Grants

IND-enabling Preclinical Studies of 2DG for Treatment of Epilepsy

NIH X01NS066866-01
BrIDGs Bridging Interventional Development Gaps
PI: Thomas Sutula, MD, PhD
This Rapid Access Interventional Development (RAID) proposal is for a preclinical translational program of pharmacokinetic, toxicological, and chemistry, manufacturing, control (CMC) studies to complete an IND application that will advance the glucose analog 2DG into human clinical trials as a novel therapy for epilepsy.